Climb Bio, Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	June 30,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$44,107	$35,685
Short-term marketable securities	139,016	65,395
Prepaid expenses and other current assets	3,513	4,769
Total current assets	186,636	105,849
Long-term marketable securities	56,098	59,572
Operating lease right-of-use assets	1,216	505
Property and equipment, net	695	288
Other long-term assets	1,649	1,530
Total assets	$246,294	$167,744
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable	$1,133	$2,269
Accrued expenses and other current liabilities	4,300	4,459
Operating lease liabilities	501	256
Total current liabilities	5,934	6,984
Operating lease liabilities, net of current portion	813	285
Total liabilities	6,747	7,269
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 250,000,000 shares authorized; 57,436,255 and 47,766,338 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	6	5
Additional paid-in capital	556,555	449,762
Accumulated other comprehensive income (loss)	(67)	435
Accumulated deficit	(316,947)	(289,727)
Total stockholders’ equity (deficit)	239,547	160,475
Total liabilities and stockholders’ equity (deficit)	$246,294	$167,744

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.